Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK.

The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which has early-phase clinical manufacturing expertise. The organisations aim to create a joined-up translational pathway that reduces complexity of manufacturing, accelerates timelines for therapy development, and strengthens the UK’s position as a global leader in advanced therapeutics.

By aligning technical transfer processes, quality systems, and regulatory expertise, the collaboration could enable more efficient transitions between early and later stages of manufacturing. This will help academic, clinical, and commercial innovators navigate the journey from proof of concept through to first-in-human trials and ultimately commercial launch.

“This collaboration is a powerful example of how the UK’s strength in early research can be matched with long-term manufacturing foresight,” said Angela Osborne, Founder & Executive Chair of eXmoor Pharma.

“CVIC is doing vital work in early-phase GMP, and by connecting that with eXmoor’s development and commercialisation expertise, we can create a clearer, more supportive route to bring promising therapies to patients. It’s about strengthening the UK ecosystem so that innovation stays here and thrives here.”

The partnership also aims to provide greater clarity to early-stage innovators on long-term commercial feasibility, while creating a platform to demonstrate robust UK-based manufacturing routes to both domestic and international stakeholders.

“For the UK’s cell and gene therapy sector to truly thrive, key learnings must flow freely across institutional and commercial boundaries,” added Owen Bain, Director of CVIC, Royal Free London NHS Foundation Trust.

“This collaboration is designed to do exactly that, connecting NHS early-phase experience with eXmoor’s development and commercial manufacturing expertise. 

“By sharing practical know-how, aligning standards, and building mutual understanding, we can catalyse the manufacturing pathway for the next wave of innovators and create a stronger, more resilient UK ecosystem for advanced therapies.”